Specifications
MLN2238 is a proteasome inhibitor. Much like Bortezomib, MLN2238 selectively and reversibly inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome, with IC50 and Ki of 3.4 nM and 0.93 nM, respectively. MLN9708 is the prodrug form of MLN2238; the two compounds are also known as ixazomib citrate and ixazomib, respectively. Under physiological conditions, the boronic citrate ester is rapidly hydrolyzed to a boronic acid. Ixazomib has been used in combination therapy as a treament for multiple myeloma, and studies indicate that it has the potential to treat other cancers as well.
Info
| Chemical Formula | C14H19BCl2N2O4 |
| CAS No. | 1072833-77-2 |
| Purity | >99% by HPLC |
| Molecular Weight | 361.03 Da |
| Physical State | Lyophilized powder |
| Quantity | 5 mg |
| Solubility | DMSO (72 mg/mL); ethanol (9 mg/mL) |
| Storage | Store dessicated as supplied at -20°C for 2 years. |
| Product can be shipped at room temperature. |
Lifesensors 是一家生物技术公司,致力于为治疗,药物发现和研究市场开发支持技术。通过提供创新的研究工具,确立了在泛素和类泛素蛋白途径中的先进地位。此外,我们的原核和真核蛋白表达平台 SUMOpro 和 SUMOstar 在世界范围内被学术、政府、制药和生物技术实体所使用